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A B S T R A C T
The review focuses on current data on Alzhemier’s dementia, a clinical syndrom characterised with acquired deterio-
ration of cognitive functioning and emotional capacities, which impaires everyday activity and quality of life. Alzhei-
mer’s dementia is the most common type of dementia in clinical surveys. The diagnosis of Alzheimer’s dementia is pri-
marily based on symptoms and signs and memory impairment is clinically most signifficant. Cholinesterase inhibitors –
donepezil, rivastigmine and galantamine are considered to be the first line pharmacotherapy for mild to moderate Alz-
heimer’s disease. Currently, no effective pharmacologic interventions have been researched enough to support their use in
prevention of Alzheimer’s dementia. Studies suggest that healthy lifestyle, ongoing education, regular physical activity,
and cholesterol control, play a role in prevention of Alzheimer’s dementia.
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Introduction
Dementia is a clinical syndrom characterised with ac-
quired deterioration of cognitive functioning and emo-
tional capacities, which impaires everyday activity and
quality of life. The dementias can be categorized accord-
ing to etiology, neuropathology or clinical presentation.
Four major groups of dementias have been defined: Alz-
heimer’s dementia (AD); the Parkinson’s group (includ-
ing Lewy Body disease, dementia of Parkinson’s and Alz-
heimer’s dementia with Parkinson’s); the frontotempo-
ral group (including Pick’s disease and Semantic demen-
tia); and the vascular group (including large and small
vessel disease1. This review focuses on the Alzheimer’s
dementia, named after german doctor Alois Alzheimer
who, in 1906, found changes in the brain (amyloid pla-
ques and neurofibrillary tangles) of a woman who died,
for that time, of an unknown mental disease.
Epidemiology
AD is the most common type of dementia in clinical
and autopsy surveys1. AD is a neurodegenerative disor-
der that is estimated to affect 15 million people around
the world2. It is estimated that by 2050 the number of pa-
tients with AD could be as high as 25 million3. The cur-
rent prevalence of AD in the U.S. is estimated at 4.5 mil-
lion, a number expected to rise threefold over the next 50
years as the population ages4.
Etiology/Risk Factors
Cerebral degeneration, with selective neuronal death
induced by extracellular amyloid deposits in the form of
senile plaques and intracellular neurofibrillary tangles
composed of helical paired tau protein, is the best-stud-
ied pathological event related to AD. Neurofibrillary tan-
gles are composed of an abnormally hyperphosphoryla-
ted intracellular protein called tau, tightly wound into
paired helical filaments and thought to impact micro-
tubule assembly and protein trafficking, resulting in the
eventual demise of neuronal viability. The extracellular
amyloid plaque deposits are composed of a proteinacious
core of insoluble aggregated amyloid-b (Ab) peptide and
have led to the foundation of the amyloid hypothesis5. In
AD, multiple regions of brain gray matter have a pro-
found neuronal loss, including basal forebrain, hippo-
campus, entorhinal, and temporal cortices. Braak and
Braak suggest that the neurodegenerative process begins
with neuronal loss in the glutamatergic pathways of the
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entorhinal cortex before extending to the hippocampus
and amygdala and then more widely to neocortical and
subcortical areas6.
The amyloid cascade hypothesis is one of the theories
of pathogenesis for Alzheimer disease7. The most impor-
tant abnormality is an excess of Ab peptides brought
about through either overproduction or failiure in degre-
dation. It seems that late-life onset AD results from a
failure of metabolism and degradation of Ab, while muta-
tions in the »Alzheimer genes« (Presenilin I, Presenilin
II, and APP) leeds to overproduction of Ab. Previously, it
was considered that the plaque was necessary to initiate
this toxic cascade, but it is now considered more likely
that the Ab monomers and oligomers initiate the process,
long before organizing into plaques.
Secondary protective responses such as microglial ac-
tivation, an inflammatory response and free radical for-
mation are part of the toxic cascade induced by amyloid
accumulation, which ultimately contributes to neuronal
death, leading to the clinical manifestations of dementia1.
Beside mutations in APP, PS1 and PS2 genes molecu-
lar genetic studies have found that polymorphisms in
APOE gene are implicated in AD pathogenesis8. APOE
has critical functions in redistributing lipids among CNS
cells for normal lipid homeostasis, repairing injured neu-
rons, maintaining synapto-dendritic connections, and sca-
venging toxins. In Alzheimer’s disease, apoE acts di-
rectly or in concert with age, head injury, oxidative
stress, ischemia, inflammation, and excess amyloid beta
peptide production to cause neurological disorders, accel-
erating progression, altering prognosis, or lowering age
of onset9.
Recent studies show that these proteins are also invol-
ved in several neuroplasticity-signaling pathways (NMDA-
-PKA-CREB-BDNF, reelin, wingless, notch, among oth-
ers). DNA damage caused by oxidative stress is not com-
pletely repaired in neurons and is accumulated in the
genes of synaptic proteins. Several functional single-nu-
cleotide polymorphisms (SNPs) in synaptic genes may be
interesting candidates to explore in AD. Thus, experi-
mental evidence shows that proteins implicated in AD
pathogenesis have differential roles in several signaling
pathways related to neuromodulation and neurotrans-
mission in adult and developing brain. It has been sug-
gested that oxidative stress effects on DNA and inherited
variations in synaptic genes may explain in part the syn-
aptic dysfunction seen in AD8.
Earlier investigations have shown that permanent ac-
tivation of glial cells in the brains of AD patients pro-
motes the production of excessive quantities of free radi-
cals, nitric oxide, and cytokines, which could be detri-
mental to neuronal cells. Damage to the blood-brain bar-
rier by inflammatory processes results in the influx of peri-
pheral immune system cells and local immune reactions10.
Glutamatergic dysfunction plays an important role in
the pathogenesis of this illness, although this distur-
bance is probably a secondary phenomenon to other
neurochemical, genetic or metabolic changes, essential to
the development of AD11.
Of approximately 200 peptides that are known to ex-
ist in the body, 80 carry out functions as neurotrans-
mitters and about 20 have been linked to AD. The most
notable points in AD could be the reduction in substance
P in the cerebral cortex, hippocampus, basal ganglia and
cephalospinal fluid; the diminished levels of somato-
statin in the same structures except for the basal ganglia;
the reduction in the amount of vasopressin except in the
temporal lobe; and the increased levels of dynorphin and
leucine enkephalin12.
Regarding risk factors, age is the strongest risk factor
for AD. Gender13, marital status14 and living in an urban
area have been suggested as possible risk factors for
AD15. Lower education has repeatedly been identified as
a risk factor for the development of AD, while higher ed-
ucation correlates with older age at onset and possibly
with lower overall risk16. This pattern has been attrib-
uted to brain and cognitive reserve. Hypertension may
impair cognitive functions and is related to the occur-
rence of not only vascular dementia but also AD, while
the relationship between cholesterol and dementia var-
ies, depending on when the cholesterol is measured over
the life course – midlife high cholesterol level appears to
be a risk factor for dementia, especially AD17. There is
also evidence for an elevated risk of both vascular de-
mentia and AD in patients with type 2 diabetes mellitus,
albeit with strong interaction of other factors such as hy-
pertension, dyslipidaemia and ApoE genotype18. Popula-
tion-based studies have shown that those with type 2 dia-
betes mellitus have an increased risk of cognitive impair-
ment, dementia, and neurodegeneration. There are many
mechanisms through which diabetes could increase risk
of dementia, including glycemia, insulin resistance, oxi-
dative stress, advanced glycation endproducts, inflam-
matory cytokines, and microvascular and macrovascular
disease19.
Investigations have targeted three so-called »Alzhei-
mer genes«, Presenilin I, Presenilin II, and APP, which
are thought to work through increased production of Ab
peptides and are held responsible for many familial cases
of AD. These genes are accounting for around 5% of
cases, usually the early-onset variant. Most AD cases,
particularly with onset after the age of 65, occur in the
absence of one of the causative genes and without an
identified family history. The major susceptibility gene
associated with late-onset AD cases is apolipoprotein e4
(APOe4). By age 85 those homozygous for the APOe4 al-
lele (2% of the population) have a 50–90% chance of de-
veloping AD, and those heterozygous for the APOe4 al-
lele (15% of the population) have a 45% chance, in
contrast to the 20% chance in the general population20,21.
Although the APOe4 allele is the only proven genetic
risk factor for the late form of the disease, genetic epide-
miological studies suggest that other loci are also in-
volved22.
It is improtant to stress the role of lifestyle in develop-
ment of AD. Patients with varied activities, including in-
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tellectual, physical, recreational and social activities, are
less likely to develop AD23. Also, social network size
seems to play a role in preserving cognitive functioning24.
Diagnostic Criteria
The diagnosis of AD is primarily based on symptoms
and signs, according to DSM-IV-TR and ICD-10 diagnos-
tic criteria. Memory impairment is clinically most signi-
fficant. The presence of characteristic symptoms such as
problems with retaining recent information or problems
to come up with words are suggestive of AD. Language,
praxis and recognition skills, are affected even early in
the presentation, while motor and sensory symptoms are
absent until late in the course of the disease. AD has a
gradual and progressive course, typically 10 years from
diagnosis to death. The cholinesterase inhibitors have
had some effect on the course of disease for individual
subjects, though population trends have been harder to
demonstrate25.
Assesment of cognitive functioning is necessary for
making initial diagnose of dementia. For this reason,
mesauring scales are used in patients with dementia for
assesment of cognitive functioning, psychopathology and
psychosocial functioning.
The most commonly used instrument for assesment
of cognitive deterioration is Mini Mental state Examina-
tion (MMSE). It takes 5–10 minutes to complete the
MMSE, and maximum result is 30 points. In many coun-
tries MMSE has become a part of routine practice26. Alz-
heimer disease assessment scale (ADAS) also measures
cognitive functioning, memory, concentration, mood, be-
havioral disturbances27. It is consisted of 21 items. The
time to complete ADAS is around 45 minutes. Severe
impairement battery (SIB) is used to asses cognitive
functioning in patients with severe AD, while Multidi-
mensional observation scale for elderly subjects (MO-
SES) is used to asses cognitive and psychosocial func-
tioning28. Cohen-Mansfield Agitation Inventory (CMAI)
is used for assesment of manifestation and frequency of
agitation in patients with dementia. Neuropsychiatric in-
ventory (NPI) is a scale used for assesment of psychopa-
thology in patients with dementia29.
Treatment
Tacrine was the first cholinesterase inhibitor appro-
ved by the Food and Drug Administration (FDA) for the
symptomatic treatment of AD but was subsequently with-
drawn from the market place due to hepatotoxicity, re-
sulting in an unacceptable risk benefit profile for the
drug5. Other cholinesterase inhibitors – donepezil, riva-
stigmine and galantamine have better safety and tolera-
bility profiles, and are considered to be the first line
pharmacotherapy for mild to moderate Alzheimer’s dis-
ease. These drugs have slightly different pharmacologi-
cal properties, but they all work by inhibiting the break-
down of acetylcholine by blocking the enzyme acetyl-
cholinesterase. Donepezil and galantamine are both se-
lective acetylcholinesterase inhibitors30,31, whereas riva-
stigmine is an inhibitor of both acetylcholinesterase and
butyrylcholinesterase32. The most that these drugs could
achieve is to modify the manifestations of Alzheimer’s
disease33.
In 2003, memantine, an N-methyl-D-aspartate (NMDA)
antagonist, was approved for the treatment of moderate
severity AD. Memantine, a moderate-affinity, voltage-de-
pendent, uncompetitive antagonist of NMDA receptor,
shows neuroprotective effects in patients with moderate-
-to-severe AD. Memantine is a drug with neuroprotective
and cognition-enhanced properties, which can be com-
bined with other treatments for AD. Thus, memantine
does not stop or reverse AD, but its moderating effect in
protecting the brain from the toxic levels of calcium, al-
lows normal signaling among brain neurons34. Oxidative
stress and glutamate induced excitotoxicity are thought
to play a critical role in the neurodegenerative process of
AD35,36. With advancing age, neurons encounter increa-
sed oxidative stress and impaired energy metabolism,
which compromise the function of proteins that control
membrane excitability and subcellular Ca(2+) dynamics.
Toxic forms of amyloid beta-peptide can induce Ca(2+)
influx into neurons by inducing membrane-associated
oxidative stress or by forming an oligomeric pore in the
membrane, thereby rendering neurons vulnerable to exci-
totoxicity and apoptosis37. Although the precise molecu-
lar mechanism of beta-amyloid protein neurotoxicity re-
mains elusive, our and other numerous findings have
demonstrated that beta-amyloid protein directly incorpo-
rated into neuronal membranes formed calcium-perme-
able ion channels (amyloid channels) and resulted in an
abnormal elevation of the intracellular calcium levels38.
Blockade of the NMDA receptor, one of the principal
excitatory glutamate receptors in the brain, has been
shown to have neuroprotective effects in a number of
acute preclinical in vitro and in vivo models39.
The mechanism of action of some new investigated
compunds include interfering with Ab aggregation, en-
hancing its metabolism, diminishing the production of
toxic Ab peptides and enhancing the enzymatic forma-
tion of non-soluble Ab peptides.
One of the therapeutic targets is the Ab itself. A num-
ber of strategies to reduce soluble Ab are currently being
employed both preclinically as well as clinically, and in-
clude antibody based approaches, and reagents that dis-
rupt the structure of Ab, such as metal chelators40.
Two b-secretase genes have been identified in hu-
mans, referred to as BACE-1 and BACE-2, colocalized
with APP in the endosomal compartment. Only BACE-1
is significantly expressed in brain, particularly in neu-
rons. Inhibition of b-secretase is one of a promising strat-
egy for treamtent of AD, and specific BACE-1 inhibitors
should have therapeutic potential to slow or halt the pro-
gression of this disease5.
Depressive symptoms are present in two thirds of pa-
tients with dementia. It is necessary to apply antidepres-
sants in those cases. Selective serotonine reuptake inhib-
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itors (SSRI’s) are the first treatment choice. Tricyclic
antidepressants (TCA’s) should be used cautiously. Nor-
triptylin has better tolerance in comparison to other
TCA’s. On the other hand, amoxapine should be avoided
because of potential of causing extrapyramidal side ef-
fects (EPS). Monoaminooxidaze inhibitors should also be
used cutiously because of their potential of causing ortho-
static hypotension, and also because their application re-
quires special diet which can be a limitiation to difficult
for some patients41,42.
Antipsychotics are indicated in cases of psychotic sym-
ptoms in demented patients. Antipsychotics with high
potency more often induce akathisia and parkinsonism
in elderly population, while antipsychotics with low po-
tency more often cause sedation, confusion, delirium and
ortostatic hypotension, along with periferal anticholiner-
gic side effects. Atypical antipsychotics are the preferred
treatment for symptoms such as delusions, hallucina-
tions, agitation and aggressive behaviour. The most wi-
dely used are olanzapine and risperidone43.
Benzodiazepines are used in the treatment of anxiety
and agitation, primarily lorazepam and oxazepam be-
cause of lack of active metabolites and because these
medications do not metabolize in liver. Side effects of
such treatment include sedation, worsening in cognitive
functioning, delirium and higher risk of falling. Anti-
convulsive medications are used as mood stabilizers in
non-psychotic patients with behavioral disorders41,42.
In a recent investigation that studied proton mag-
netic resonance spectroscopy (1H-MRS) changes in early
to intermediate (3–6 weeks) responders to antidepres-
sant treatment with selective serotonin reuptake inhibi-
tors, authors concluded that significant increase in cho-
line to creatine ratio from the first to the second spectro-
scopic scan during the antidepressant treatment, com-
pared to almost identical values of N-acetyl-aspartate
(NAA) to creatine ratio, suggested increased turnover of
cell membranes as a mechanism of the early response to
the antidepressant drug therapy44. In the study that
aimed to assess whether changes in 1H-MRS measurable
metabolites correlate with clinical outcome after donepe-
zil treatment, the results indicated possible modest done-
pezil effect on prevention of neuronal functional deterio-
ration in dorsolateral prefrontal cortex (DLPFC) which
correlates with clinical outcome and point the use of
1HMRS as technique of help in assessment of drug
effect45.
Elderly population is more sensitive to pharmaco-
therapy, as a result of changes in pharmacodynamics
(changes in number of neurons, changes of receptors)
and pharmacokinetics (changes in absorption, distribu-
tion, metabolism, excretion and protein binding). Bear-
ing this in mind, the lowest effective doses of psycho-
pharmacs are to be used, following the general rule
»start low, go slow«, avoiding side effects as much as pos-
sible. It is necessary to recognize potential reasons for
not taking therapy, such as living alone, impaired sight
and/or hearing, and cognitive deterioration. Also, it is
necessary to consider possibility of interactions between
psychopharmacs and other medications, especially con-
sidering changes in pharmacodynamics and pharmaco-
kinetics. It is assumed that in the future treatment effi-
cacy will be monitored in vivo through amyloid imaging
and serum/CSF biomarkers.
Many preventive approaches to AD have been identi-
fied, but no randomized controlled trials (RCTs) support
their efficacy. Evidence from RCTs supports the effec-
tiveness of blood pressure control in reducing incidence
of AD, but demonstrates that postmenopausal women’s
use of estrogen is ineffective in reducing it. Observa-
tional studies suggest that some preventive approaches,
such as healthy lifestyle, ongoing education, regular phy-
sical activity, and cholesterol control, play a role in pre-
vention of AD. These approaches can and should be used
for every patient because they carry no significant risk.
Currently, no effective pharmacologic interventions have
been researched enough to support their use in preven-
tion of AD46.
An interaction between the negative effects of aging
and the positive plasticity processes associated with envi-
ronmental enrichment can provide a counterbalance th-
rough which neuronal circuitry activity coding for speci-
fic cognitive ormotor behavior could be restored47. Health
professionals should educate patients, especially patients
at higher risk of AD, about preventive strategies and po-
tentially modifiable risk factors.
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ALZHEIMEROVA DEMENCIJA: PREGLED NOVIH SAZNANJA
S A @ E T A K
Ovaj pregled se usredoto~uje na nove spoznaje o Alzheimerovoj demenciji, klini~ki sindrom karakteriziran ste~enim
o{te}enjem kognitivnih funkcija i emocionalnih kapaciteta, koji dovodi do o{te}enja svakodnevnog funkcioniranja i
kvalitete `ivota. Alzheimerova demencija naj~e{}i je tip demencije u klini~kim istra`ivanjima. Dijagnoza Alzheimerove
demencije primarno je bazirana na simptomima i znakovima, pri ~emu je o{te}enje pam}enja klini~ki najzna~ajnije.
Inhibitori kolinesteraze – donepezil, rivastigmin i galantamin smatraju se prvom linijom farmakoterapije za blage do
umjerene oblike Alzheimerove demencije. Do sada istra`ivanjima nije potvr|eno farmakolo{ko lije~enje koje bi bilo
u~inkovito u prevenciji Alzheimerove demencije. Istra`ivanja ukazuju da zdravi stil `ivota, kontinuirana edukacija,
redovita tjelesna aktivnost i kontrola razine kolesterola imaju zna~ajnu ulogu u prevenciji Alzheimerove demencije.
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